A biopharmaceutical company focused on developing innovative ophthalmic treatments, Oculis has announced the closing of an oversubscribed $ 57 million Series C financing round.
Headquartered at the EPFL Innovation Park in Lausanne, Oculis has a robust and expansive development portfolio including late-stage novel topical (eye drop) treatments, which are non-invasive and represent an unprecedented technical advance for patients with retinal edema and front-of-the-eye diseases. In addition, Oculis’ formulation discovery and innovation capabilities enable the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.
The Vaud-based company has closed a $57 million Series C financing round co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures and EarlyBird. Proceeds from this financing will accelerate Oculis’ strategy. The targeted milestones cover the development of novel topical therapies for ophthalmic diseases targeting the retina and anterior segment with high unmet needs.
Zhi Yang, Managing Partner at BVCF Management, said : “Oculis’ innovative science and transformative topical approach to address sight-threatening diseases have the potential to significantly extend the reach of such therapies to larger numbers of patients, improving accessibility and compliance and ultimately clinical outcomes. This unrivalled potential, the strength of the international team at Oculis, and growing unmet medical needs in major key markets around the world are the key factors behind the decision by BVCF and our fellow investors to participate in this new financing round.”
